



## **Mersana Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference**

January 2, 2019

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 37<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2019 at 3:00 p.m. PT.

A live webcast of the presentation and Q&A session will be available on the Investors & Media section of Mersana's website at [www.mersana.com](http://www.mersana.com). An archived replay will be available for approximately 90 days following the presentation.

### **About Mersana Therapeutics**

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company's second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.

### **Investor & Media Contact**

Sarah Carmody  
[scarmody@mersana.com](mailto:scarmody@mersana.com)  
617-844-8577



Source: Mersana Therapeutics, Inc.